A detailed history of D. E. Shaw & Co., Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,108,647 shares of RNA stock, worth $38.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,108,647
Holding current value
$38.4 Million
% of portfolio
0.05%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $13.8 Million - $17.8 Million
369,608 Added 50.01%
1,108,647 $50.9 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $16.1 Million - $28.9 Million
707,773 Added 2263.71%
739,039 $30.2 Million
Q1 2024

May 15, 2024

SELL
$9.16 - $25.52 $93,615 - $260,814
-10,220 Reduced 24.63%
31,266 $797,000
Q4 2023

Feb 14, 2024

SELL
$4.87 - $9.37 $544,431 - $1.05 Million
-111,793 Reduced 72.93%
41,486 $375,000
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $1,644 - $2,962
261 Added 0.17%
153,279 $977,000
Q2 2023

Aug 14, 2023

SELL
$10.62 - $17.34 $2.48 Million - $4.05 Million
-233,332 Reduced 60.39%
153,018 $1.7 Million
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $2.11 Million - $3.52 Million
137,189 Added 55.06%
386,350 $5.93 Million
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $2.51 Million - $5.65 Million
249,161 New
249,161 $5.53 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.81B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.